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S352 Poster Session IIALL with leukocytes .30/nl at diagnosis and/or delayed CR (.4
weeks), pro B-ALL or complex karyotype, T lineage ALL (prae T-
ALL, mature T-ALL) and standard risk ALL (SR-ALL) with molec-
ular persistence or relapse are candidates for SCT in CR1. Pts with
siblings have a 25% probability (prob) of an HLA identical sibling.
Pts without an HLA identical sibling have a chance of 80% to find
a compatible unrelated donor.
Here, we report our single centre data on SCT from sibling and
unrelated donors. High resolution HLA typing class I+II was done
since 01/2006. Between 2006 and 2010, 36 pts with ALL, CR1 un-
derwent SCT. 12 pts had a sibling donor, 14 pts an HLA identical
unrelated donor (MUD) and 10 pts an HLA compatible unrelated
donor (MMUD). All HLA mismatches were in class I, 9/10 pairs
had 1 mismatch (HLA-C antigen 4, HLA-A antigen 3, HLA-B allele
2) and 1/10 pairs had 2 mismatches (HLA-C antigen and HLA-B al-
lele). Median age was 43 (18-67) years (yrs), not different between
sibling or unrelated SCT. Indication for SCT: 14/36 pts belonged
to the VHR group, 19/36 pts to the HR group and 3/36 pts of the
SR group had molecular relapse. All pts were transplanted in CR1
(bone marrow \5% blasts). Conditioning was myeloablative
(MAC) in 30/36 pts (12 Gy TBI and VP 16 or CY 29, other 1) and
in 6/36 pts reduced intensity (RIC). Pts with unrelated donors re-
ceived antithymocyte globuline (ATG) (60mg/kg in MAC, 40mg/
kg in RIC).
Results: 25/36 pts are alive in CR (median f/u 40 months, 7-66), 11/
36 pts died 8 months (0.5-24) after SCT. Causes of death: leukemia
3, infection6GvHD 6, other 2. Prob of OS for all pts (36) at 4 yrs is
0.65, 0.82 for SCT with sibling donors, 0.52 for MUD-SCT, 0.56
for MMUD-SCT. The differences were not significant. Prob of
LFS is 0.59 for all pts, in pts with sibling donors 0.82, after MUD-
SCT 0.49 and 0.44 after MMUD-SCT. Prob of NRM for all pts
was 0.26, in sibling SCT 0.18, in MUD-SCT 0.34 and in
MMUD-SCT 0.26.
Conclusion: In ALL, CR1 SCT afterMAC and with a sibling donor
is still the gold standard (OS 0.82). In unrelated donor SCTwe found
no difference in survival between HLA identical or 1 antigen mis-
matched donor-recipient pairs. It has to be discussed if dose reduc-
tion of ATG in MUD-SCT might improve the results by
decreasing NRM and relapse post SCT.400
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Background:Allogeneic stem cell transplantation (allo-SCT) is lim-
ited by transplant-related-mortality (TRM), primarily mediated by
graft-versus-host disease (GVHD). Disease specific preparative reg-
imens that offer acceptable graft-versus-host disease (GVHD)-asso-
ciated morbidity and TRM are preferred. The B-cell lymphoma
specific nonablative (NST) regimen fludarabine, cyclophosphamide
and rituximab (FCR) is reportedly safe and effective, however most
reported data are from single institution.
Methods: Twenty six pts with recurrent CD20+ B-cell lymphoid
malignancies received FCR NST allo-SCT between March 2008
and May 2011. The conditioning regimen consisted of fludarabine
(30 mg/m2 daily for 4 days), cyclophosphamide (750 mg/m2 daily
for 3 days) and rituximab (375 mg/m2, day-13,-6,+1,+8). This was
followed by either related (n 5 18) or unrelated donors (n 5 8)
allo-SCT. All patients received tacrolimus and mini-methotrexate
GVHD prophylaxis (rATG for unrelated donor allo-SCT).
Results: The median age of pts at transplantation was 59 years
(range 41-64). Ten pts had CLL, 7 MCL, 3 DLBCL, 3 FL and 3
transformed-lymphoma. At diagnosis, 20 (77%) pts had stage IV dis-
ease. Twenty three pts (88%) received $3, 14 (54%) $4 regimens
and 4 (15%) had prior autologous-SCT. Nine (35%) pts were in
complete remission pre-SCT following salvage therapy. At the
time of analysis, 17 pts were alive with an estimated 2-year OS and
PFS of 63%, and non-relapse mortality (NRM) 25%. Grade II-IV
aGVHD occurred in 8 (31%) pts and chronic GVHD in 6 (24%)pts (extensive 5 3). Causes of death includes progressive disease 4,
aGVHD2 (both after receivingDLI formixed chimerismwith resid-
ual disease), infection 1 and others 2 (substance abuse, leucoence-
phalopathy). Only 6 pts required re-hospitalization within 100
days of SCT, (average 10 days; range, 3-18).
Conclusion: Our data suggests nonablative FCR conditioning reg-
imen is safe and effective in heavily pre-treated B-cell lymphoid ma-
lignancies. While our conclusion is limited by the small sample size,
this suggests the need for larger prospective studies to validate the ef-
ficacy of FCR and to compare it with other reduced-intensity condi-
tioning allo-SCT in B-cell malignancies. We recommend that FCR
allo-SCT be considered early and novel strategies (radioimmuno-
therapy, tandem auto-allo-SCT) be incorporated and evaluated to
major cause of failure, particularly in heavily pre-treated pts.401
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Post transplant lymphoproliferative disorder (PTLD) is a hetero-
geneous disease ranging from benign polyclonal proliferation of B
cells to monoclonal B cell proliferation. Its cumulative incidence is
about 1% with most cases observed during the first year. Most cases
are associated with Epstein-Barr virus (EBV) infection. Indolent
lymphomas are not considered part of PTLD in the WHO 2008
classification.
Here we describe two cases of EBV related post transplant lym-
phoplasmacytic lymphoma (LPL) with multiorgan failure and ag-
gressive course. The first patient was an EBV positive 28-year old
male with refractory Hodgkin’s lymphoma following autologous
transplant. The second was an EBV negative 57-year old male
with relapsed peripheral T-cell lymphoma, otherwise non-specified.
They underwentmatched unrelated allogeneic transplant after being
conditioned with fludarabine, busulfan and ATG. They received
methotrexate and cyclosporine for GVHD prophylaxis. On Day
+20 post transplant, the first patient presented with fever, nausea, di-
arrhea, and bilateral cervical lymphadenopathy. He had pancytope-
nia, elevated liver enzymes, and acute renal failure. Bone marrow
aspirate and biopsy findings were consistent with monomorphic
LPL with normal cytogenetics. Biopsies of a cervical lymph node,
duodenum and a colonic mass revealed the same histology. Serum
protein immunofixation (SPIF) showed biclonal IgG kappa and
lambda, IgA kappa and biclonal IgM lambda gammopathy. EBV
PCRwas 0.597x106 copies/ml.Hewas treated with immunosuppres-
sion tapering, cyclophosphamide and rituximab with no evidence of
improvement. The second patient presented with fever on day +35
post transplant. He had cervical, retroperitoneal and inguinal lymph-
adenopathy, splenomegaly, as well as pancytopenia, elevated liver
enzymes and acute renal failure. Bonemarrow aspirate and biopsy re-
vealed a monomorphic LPL. SPIF showed biclonal IgG kappa para-
protein with lambda chains. EBV PCR was 1.38x106 copies/ml. He
was treated with immunosuppression tapering and rituximab but his
condition deteriorated rapidly.
We described two cases of EBV driven post transplant LPL with
profound protein abnormalities and multiorgan failure despite indo-
lent morphology. Although indolent lymphomas are not considered
part of PTLD, clinicians must be aware of this presentation. Severity
of cases and lackof response to treatment should further bring intodis-
cussion the role of EBV load regular monitoring in patients at risk.402
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Chimerism testing, or themeasurement of the percent of recipient
and donor hematopoietic cell origin, is a standard of care for HSCT
recipients. For leukemic recipients, the quantification of chimerism
